Skip to main content

Table 1 Patients with idiopathic membranous nephropathy with thromboembolic events*

From: Proteinuria and hypoalbuminemia are risk factors for thromboembolic events in patients with idiopathic membranous nephropathy: an observational study

  Age (y) Sex Year of diagnosis Type of event, test (treatment) Serum albumin (mg/dl), proteinuria (g/24 h) Time to diagnosis (mth)
1 68 M 1995 PE, V/Q (Pred + CycloP) 1.8, 14 - 2
2 43 M 1998 PE, V/Q (Pred + CycloP) 1.7, 14 - 1
3 82 M 1999 IleofemDVT#, US (spontaneous remission) 2.0, 12 + 6
4 58 M 2000 PE, V/Q (Pred + CycloP) 1.9, 11 0
5 58 F 2001 RVT, US (Pred + CycloP) 2.1, 7 0
6 68 F 2002 PE, CTPA (Pred + CycloP) 2.2, 5 0
7 79 M 2002 PE#, CTPA (Pred + MMF) 2.8, 9 + 2
8 72 M 2003 CVA# (Pred + MMF) 1.7, 14 + 3
9 50 M 2003 DVT, US (Pred + CycloP) 1.5, 12 - 2
10 64 F 2004 DVT, US (Pred + CycloP) 2.2, 5 - 0.5
11 42 M 2005 PE, CTPA (spontaneous remission) 2.0, 12 0
12 22 M 2005 PE, CTPA (Pred + CsA) 1.2, 12 0
13 39 M 2005 PE#, CTPA (Pred + CycloP) 1.9, 11 + 1
14 61 M 2007 PE#, CTPA (Pred + CycloP) 1.6, 12 + 1
  1. *14/15 had complete data sets.
  2. PE, pulmonary embolism; V/Q, ventilation/perfusion; RVT, renal vein thrombosis; CTPA, computed tomographic pulmonary angiogram; CVA, cerebrovascular accident; DVT, deep vein thrombosis; Pred, prednisolone; CsA, ciclosporin; CycloP, cyclophosphamide; MMF, mycophenolate mofetil.
  3. All the patients who presented with TEs (patient 1, 2, 4, 5, 6, 9 – 12; 64%) were immediately anticoagulated on confirmation of the diagnosis of TE.
  4. #Not on prophylactic anti-coagulation.